Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Scholar rock - The Real Truth

3 Beaten-Down Stocks With Rebound Potential This Earnings Season

These firms present at least a modest risk/reward profile, but could be preparing for a share price turnaround depending upon how earnings season plays out.

MarketBeat · Nov 12, 2025

Alpha Buying: 3 Stocks With Sky-High Insider Confidence

When markets grow chaotic, insider buying often becomes a quiet but powerful signal. Executives and directors rarely step into the open market during periods of turmoil unless they see something the rest of us do not. In the past few weeks, as headlines have been dominated by the renewed trade…

Benzinga · Oct 14, 2025

Why Is Scholar Rock Stock Trading Lower On Monday?

Scholar Rock Holding Inc. (NASDAQ:SRRK) stock is falling on Monday with a session volume of 8.19 million versus the average volume of 2.08 million, as per data from Benzinga Pro.

Benzinga · Oct 13, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

The U.S. Food and Drug Administration (FDA) on Tuesday issued a Complete Response Letter (CRL) for Scholar Rock’s (NASDAQ:SRRK) apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA).

Benzinga · Sep 23, 2025

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24.

Benzinga · Nov 25, 2024

Why Scholar Rock Shares Are Trading Higher Today

Scholar Rock Holding Corp (NASDAQ:SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy (SMA) receiving an SMN therapy. The trial assessed patient outcomes after 24 months of treatment. All 35 non-ambulatory patients (Cohorts 2 and 3) and…

Benzinga · Jun 17, 2022

Coverage From

Organisations

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.